🔴 Abcellera Biologics is trading 4.22% down — no clear catalyst identified

Abcellera Biologics is trading 4.22% down at $13.97, with no clear catalyst identified for the October 1 decline.

• The scheduled ABCL635 Phase 2 data presentation at the International Menopause Society congress was previously announced and does not establish a cause.
• Recent coverage cited JPMorgan’s Overweight initiation and $17 price target, followed by some profit-taking after an extended run; this is background, not a confirmed explanation.
• Broader indices were only modestly lower, offering no clear market-wide explanation.